Phase 1b Open-Label Study of VRG50635 in Sporadic and Familial Amyotrophic Lateral Sclerosis Patients with Long-Term Treatment

The primary objective of this study is to evaluate the safety and tolerability of **VRG50635** in participants with **Amyotrophic Lateral Sclerosis** (ALS), both sporadic and familial forms. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to muscle weakness and atrophy. Understanding the safety profile of VRG50635 is crucial for determining its potential as a therapeutic option for ALS, a condition with limited treatment options and significant clinical need.

The clinical trial involves a total of **11 participants** diagnosed with **Amyotrophic Lateral Sclerosis**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected to include a vulnerable population, although specific selection criteria are not provided. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The general health status of the participants is not detailed, and the sponsor has not provided information on the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed as a **Phase 1b**, open-label, multiple ascending dose, multicenter study focusing on participants with **Amyotrophic Lateral Sclerosis** (ALS), both sporadic and familial forms. The trial is set to commence on February 1, 2024, with an estimated completion date of June 30, 2026. The study aims to evaluate the safety, tolerability, and potential efficacy of the investigational product VRG50635 over a long-term treatment period. Participants will be involved in the trial for its entire duration unless specific conditions necessitate early termination, such as adverse events or withdrawal of consent.

The trial will include a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will undergo a series of follow-up visits at regular intervals to monitor their response to the treatment and any potential side effects. These visits will include comprehensive assessments, such as physical examinations, laboratory tests, and questionnaires, to gather data on the drug's impact on ALS symptoms and progression. The end-of-study visit will conclude the participant's involvement, where final evaluations will be conducted to assess the overall outcomes of the treatment.

Participants are expected to adhere to the study protocol throughout the trial period. Conditions that may lead to early termination from the study include significant protocol deviations, the occurrence of serious adverse events, or the participant's decision to withdraw from the study. The trial's design and procedures are structured to ensure the collection of robust and reliable data, contributing to the understanding of VRG50635's potential as a therapeutic option for ALS.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatments comprehensively.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on February 1, 2024, with an estimated completion date of June 30, 2026. The efficacy assessment will be conducted in accordance with the trial's protocol, which is structured to ensure rigorous evaluation of the investigational product's impact on the specified medical condition. The trial will employ standardized methods for measuring and analyzing efficacy parameters, although specific endpoints and measurement tools are not detailed in the provided data. The trial's design and execution will adhere to established clinical research standards to ensure the reliability and validity of the efficacy outcomes.